Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDTelix Pharmaceuticals Limited Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.07 | -$0.07 | -$0.07 |
| Q2 2025 | 1 | -$0.07 | -$0.06 | -$0.07 |
| Q3 2025 | 1 | -$0.07 | -$0.06 | -$0.06 |
| Q4 2025 | 1 | $0.11 | $0.11 | $0.11 |
| Q1 2026 | 1 | -$0.14 | -$0.13 | -$0.14 |
| Q2 2026 | 1 | -$0.09 | -$0.08 | -$0.09 |
| Q3 2026 | 1 | -$0.14 | -$0.13 | -$0.13 |
| Q4 2026 | 1 | -$0.08 | -$0.08 | -$0.08 |
| Q1 2027 | 1 | $0.06 | $0.06 | $0.06 |
| Q2 2027 | 1 | $0.08 | $0.08 | $0.08 |
| Q3 2027 | 1 | $0.14 | $0.15 | $0.14 |
| Q4 2027 | 1 | $0.14 | $0.15 | $0.14 |
| Q1 2028 | 1 | $0.14 | $0.15 | $0.15 |
| Q2 2028 | 1 | $0.21 | $0.22 | $0.21 |
| Q3 2028 | 1 | $0.23 | $0.25 | $0.24 |
| Q4 2028 | 1 | $0.20 | $0.21 | $0.21 |
| Q1 2029 | 1 | $0.35 | $0.37 | $0.36 |
| Q2 2029 | 1 | $0.14 | $0.15 | $0.15 |
| Q3 2029 | 1 | $0.28 | $0.30 | $0.29 |
Telix Pharmaceuticals Limited Earnings Date And Information
Telix Pharmaceuticals Limited last posted its earnings results on Wednesday, August 20th, 2025. The company reported $-0.00677 earnings per share for the quarter, topping analysts' consensus estimates of $-0.139 by $0.13223. The company had revenue of 593.11 M for the quarter and had revenue of 783.21 M for the year. Telix Pharmaceuticals Limited has generated $0 earnings per share over the last year ($0.14 diluted earnings per share) and currently has a price-to-earnings ratio of 143.69. Telix Pharmaceuticals Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 18th, 2026 based on prior year's report dates.
Telix Pharmaceuticals Limited Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 06/30/2025 | Q2 2025 | N/A | -$0.01 | N/A | $2.94 M | $593.11 M |
| 02/24/2025 | Q4 2024 | N/A | $0.12 | N/A | N/A | $594.24 M |
| 06/28/2024 | Q2 2024 | N/A | $0.03 | N/A | $18.85 M | $188.96 M |
| 12/30/2023 | Q4 2023 | N/A | $0.06 | N/A | $55.07 M | $281.71 M |
| 06/29/2023 | Q2 2023 | N/A | -$0.05 | N/A | $42.86 M | $220.83 M |
| 12/30/2022 | Q4 2022 | N/A | -$0.10 | N/A | $16.65 M | $136.05 M |
| 06/29/2022 | Q2 2022 | N/A | -$0.23 | N/A | N/A | $24.05 M |
| 12/30/2021 | Q4 2021 | N/A | -$0.17 | N/A | N/A | $4.69 M |
| 06/29/2021 | Q2 2021 | N/A | -$0.12 | N/A | N/A | $2.91 M |
| 12/30/2020 | Q4 2020 | N/A | -$0.10 | N/A | N/A | $3.61 M |
| 06/29/2020 | Q2 2020 | N/A | -$0.07 | N/A | N/A | $1.61 M |
| 12/30/2019 | Q4 2019 | N/A | -$0.07 | N/A | N/A | $1.67 M |
| 06/29/2019 | Q2 2019 | N/A | -$0.05 | N/A | N/A | $1.82 M |
| 12/31/2018 | Q4 2018 | N/A | -$0.04 | N/A | N/A | $195.00 K |
| 06/30/2018 | Q2 2018 | N/A | -$0.03 | N/A | N/A | $0 |
| 12/31/2017 | Q4 2017 | N/A | -$0.02 | N/A | N/A | $48.79 K |
| 06/30/2017 | Q2 2017 | N/A | -$0.02 | N/A | N/A | $0 |
| 01/30/2017 | Q4 2016 | N/A | -$0.01 | N/A | N/A | $0 |
| 06/30/2016 | Q2 2016 | N/A | $0.01 | N/A | N/A | $0 |
| 12/30/2015 | Q4 2015 | N/A | -$0.00 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Telix Pharmaceuticals Limited Earnings: FAQ's
Telix Pharmaceuticals Limited has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 18th, 2026 based offlast year's report dates.
In the previous quarter, Telix Pharmaceuticals Limited (:TLX) reported $-0.00677 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.139 by $0.13223.
The conference call for Telix Pharmaceuticals Limited's latest earnings report can be listened to online.
The conference call transcript for Telix Pharmaceuticals Limited's latest earnings report can be read online.
Telix Pharmaceuticals Limited (:TLX) has a recorded annual revenue of $783.21 M.
Telix Pharmaceuticals Limited (:TLX) has a recorded net income of $49.92 M.Telix Pharmaceuticals Limited has generated $0.15 earnings per share over the last four quarters.
Telix Pharmaceuticals Limited (:TLX) has a price-to-earnings ratio of 143.69 and price/earnings-to-growth ratio is -5.39.